Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam

Matteo Bassetti; Maddalena Peghin; Alessio Mesini; Elio Castagnola

doi:10.2147/IDR.S209264

Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam

Infect Drug Resist. 2020 Jun 12:13:1763-1773. doi: 10.2147/IDR.S209264. eCollection 2020.

Authors

Matteo Bassetti^{1

2}, Maddalena Peghin¹, Alessio Mesini³, Elio Castagnola³

Affiliations

¹ Infectious Diseases Clinic, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy.
² Department of Health Sciences, University of Genoa, Genoa, Italy.
³ Division of Infectious Diseases, IRCCS Istituto Giannina Gaslini, Genoa, Italy.

Abstract

Antimicrobial resistance poses a substantial threat to global public health. The pursuit of new antibiotics has decreased and very few options have been investigated for the treatment of complicated multidrug-resistant Gram-negative (MDR-GN) infections in adult population and even less in pediatric patients. Ceftazidime-avibactam (CAZ-AVI) is novel cephalosporin/β-lactamase inhibitor (BL-BLI) combination with broad antibacterial spectrum. The aim of this review is to describe the current and future role CAZ-AVI in the pediatric population with suspected or confirmed MDR-GN infections.

Keywords: ceftazidime/avibactam; infections; multidrug-resistant Gram-negative; pediatric.

Publication types

Review